Docetaxel liposomal (Azaya Therapeutics)

多西他赛脂质体 (Azaya Therapeutics)

Report date: 2022/11/21 19:26:43

Base Information

Drug NameDocetaxel liposomal (Azaya Therapeutics)
Drug Alias NameDocePLUSATI-1123AZD 1123CAN-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitosis inhibitorsTubulin modulatorsTubulin polymerisation promoters
TargetsTubulin
Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAzaya Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAzaya Therapeutics IncCanbridge Life Sciences Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A